Pfizer has settled an ongoing battle with Teva Pharmaceuticals and several other parties to prevent the sale of Teva’s copycat version of the world’s best-selling drug, Lipitor (atorvastatin).
Under the terms of the agreement Teva, Phoenix Healthcare Distribution, Barclay Pharmaceuticals, AAH Pharmaceuticals, L Rowland & Co and Day Lewis will not the generic before May 2012, when the patent expires.
Go deeper with GlobalData
Pfizer commenced legal proceedings against Teva and three major wholesalers in July.
Upon the decision of a full trial, Pfizer said in a statement that Teva acknowledges that the Lipitor patent is valid and infringed by Teva’s product.
In November, Pfizer will launch a chewable low-dose version of Lipitor in the EU.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
